Major shareholder announcement
29 Janvier 2024 - 1:13PM
Major shareholder announcement
Major shareholder
announcement
|
January 29, 2024Company announcement No. 03 |
|
|
On January 29, 2024, following the satisfaction
of all conditions precedent, the combination of Novozymes A/S
("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") by way of
a statutory merger of the two companies (the "Combination"), was
successfully completed. Reference is made to Novozymes' company
announcement no. 2 of January 29, 2024.
Pursuant to Section 30 of the Danish Capital
Markets Act, Novozymes hereby announces that Novo Nordisk Fonden
has on its own behalf and on behalf of its wholly owned subsidiary
Novo Holdings A/S notified Novozymes, that as of completion of the
Combination on January 29, 2024, Novo Nordisk Fonden and Novo
Holdings A/S, indirectly and directly, respectively, holds a total
of 53,743,600 Novozymes A-shares (nominally DKK 107,487,200) and
58,048,725 Novozymes B-shares (nominally DKK 116,097,450)
corresponding to 23.87% of the entire issued share capital and
62.55% of the total voting rights in Novozymes.
|
Contact information |
| Investor
Relations |
|
|
| Tobias Bjorklund |
+45 3077 8682 |
tobb@novozymes.com |
| Anders Enevoldsen |
+45 5350 1453 |
adev@novozymes.com |
| Media
Relations |
|
|
| Lina Danstrup |
+45 3077 0552 |
lind@novozymes.com |
| |
|
|
- 2024_03_Major_Shareholder_Announcement
Novonesis AS (TG:NZM2)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Novonesis AS (TG:NZM2)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
